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Abstract
Despite initial and sometimes dramatic responses of specific NSCLC tumors to EGFR TKIs, nearly all will develop resistance
and relapse. Gene expression analysis of NSCLC cell lines treated with the EGFR TKI, gefitinib, revealed increased levels of
FGFR2 and FGFR3 mRNA. Analysis of gefitinib action on a larger panel of NSCLC cell lines verified that FGFR2 and FGFR3
expression is increased at the mRNA and protein level in NSCLC cell lines in which the EGFR is dominant for growth
signaling, but not in cell lines where EGFR signaling is absent. A luciferase reporter containing 2.5 kilobases of fgfr2 59
flanking sequence was activated after gefitinib treatment, indicating transcriptional regulation as a contributing mechanism
controlling increased FGFR2 expression. Induction of FGFR2 and FGFR3 protein as well as fgfr2-luc activity was also observed
with Erbitux, an EGFR-specific monoclonal antibody. Moreover, inhibitors of c-Src and MEK stimulated fgfr2-luc activity to a
similar degree as gefitinib, suggesting that these pathways may mediate EGFR-dependent repression of FGFR2 and FGFR3.
Importantly, our studies demonstrate that EGFR TKI-induced FGFR2 and FGFR3 are capable of mediating FGF2 and FGF7
stimulated ERK activation as well as FGF-stimulated transformed growth in the setting of EGFR TKIs. In conclusion, this study
highlights EGFR TKI-induced FGFR2 and FGFR3 signaling as a novel and rapid mechanism of acquired resistance to EGFR
TKIs and suggests that treatment of NSCLC patients with combinations of EGFR and FGFR specific TKIs may be a strategy to
enhance efficacy of single EGFR inhibitors.
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Introduction
A general goal of molecular studies in cancer is to dissect the
dominant oncogenic pathways and highlight specific components
of these pathways as therapeutic targets. In this manner, the
EGFR has emerged over the past years as an important target that
likely plays key roles in non-small cell lung cancer (NSCLC) [1,2].
The small molecule tyrosine kinase inhibitors (TKIs), gefitinib and
erlotinib, were developed and deployed as experimental thera-
peutics in NSCLC [3]. While the spectrum of NSCLC patients
that exhibit objective responses to gefitinib or erlotinib is
disappointingly narrow [4], the positive activity on a defined
subpopulation of NSCLC patients in which EGFR is a dominant
oncogene is reason for optimism for continued development of
novel targeted therapeutics to other oncogenes in lung cancer.
Among the NSCLC patients who initially respond to EGFR
TKIs, all will eventually relapse (reviewed [5]). In fact, acquired
resistance to single targeted molecular therapies is a general
problem in cancer treatment. Chronic myelogenous leukemia
(CML) patients treated with imatinib, a BCR-Abl inhibitor, can
undergo relapse due to the acquisition of a secondary mutation
within the Abl coding sequence [6,7] that renders imatinib
ineffective. Similarly, EGFR TKI responsive patients acquire
secondary mutations, T790M in the ATP binding cleft, which
increases EGFR affinity for ATP (reviewed in [8]). Aside from
acquisition of secondary mutations, alternative receptor tyrosine
kinase signaling can lead to acquired resistance to EGFR TKIs.
For example, c-Met amplifications following EGFR TKI treat-
ment contribute to acquired resistance to EGFR TKIs [9]. IGF-IR
has also been reported to be hyperphosphorylated following
EGFR TKI treatment [10]. Therefore, alternative signaling
pathways mediating self-sufficiency in growth will need to be
identified and targeted.
Clinical and biological evidence suggest that EGFR signaling is
only one important signaling pathway in lung cancer. If self-
sufficiency in growth is a hallmark of cancer, then additional
receptor tyrosine kinases capable of signaling for growth, which
render EGFR autocrine signaling redundant, can account for the
reduced effectiveness of EGFR TKIs in lung cancer. Multiple
studies support the hypothesis that EGFR independent receptor
tyrosine kinase signaling pathways are active in EGFR TKI
insensitive NSCLC [11,12,13]. In particular FGFR autocrine
signaling has been implicated in NSCLC cell lines [11]. FGFs and
their receptors (FGFRs) are involved in multiple cellular functions.
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esis through cell proliferation, differentiation, and cell migration.
In adults, FGFs are involved in wound healing and tissue repair as
well as regulating the nervous system. Unfortunately, they also
contribute to tumor angiogenesis [14,15]. Numerous in vitro studies
reveal frequent co-expression of specific FGFs as well as FGFR1
and FGFR2 [11,13,16,17,18,19]. Primary NSCLC specimens also
show co-expression of FGF2, FGFR1, and FGFR2 [20].
Importantly, inhibition of FGFR signaling via dominant-negative
FGFR1 [18], FGF2 neutralizing antibodies [19], FGFR TKI [11]
or anti-sense RNA [11,19] approaches blocked proliferation of
tumor growth in NSCLC. These studies suggest FGF-FGFR co-
expression can function as an autocrine growth pathway,
particularly in NSCLC cells lines intrinsically resistant to EGFR
TKIs [11]. In this study, we present evidence for a novel role of
FGFR2 and FGFR3 in acquired resistance to EGFR TKIs in
NSCLC cells.
Results
FGFR2 and FGFR3 expression is induced after EGFR
inhibition
Total RNA from H322c NSCLC cells treated 4 days with
DMSO (0.1%) as a control or with the EGFR TKI, gefitinib, was
purified and used to probe Affymetrix human U133 plus 2.0
arrays. Gene expression changes detected by microarray analysis
revealed induction of FGFR2 and FGFR3 but not FGFR1,
FGFR4, or FGFR ligands in gefitinib treated cells (Table S1).
Other tyrosine kinases, such as Met and IGF1R, which are
reported to be important for acquired resistance to EGFR
inhibitors [9,10], were not induced over control treatment.
Quantitative RT-PCR analysis of 9 NSCLC cell lines previously
characterized for sensitivity to the EGFR inhibitor gefitinib [21]
and the FGFR inhibitor RO4383596 [11] confirmed the induction
of FGFR2 and FGFR3 expression changes in a larger panel of
NSCLC cells. Interestingly, FGFR2 and FGFR3 expression was
induced in all NSCLC cells that have been shown to be gefitinib
sensitive (H322c, HCC827, HCC4006) and correlated with cells
that co-express EGFR and EGF ligands (H322c, H1334, Calu3) or
bear gain-of-function EGFR (HCC827, HCC4006, H1650)
(Figure 1A). NSCLC cells that do not express EGFR (H661,
H520) or are resistant to gefitinib (H226) [11] did not exhibit
FGFR2 and FGFR3 mRNA induction in response to gefitinib
(Figure 1A). This indicates that FGFR induction in response to
gefitinib is not due to off-target effects of the drug, but is related to
targeted effects on functional EGFR signaling. FGFR2 and
FGFR3 protein levels as assessed by immunoblot analysis
coincided with FGFR2 and FGFR3 mRNA measured by
quantitative RT-PCR. As shown in Figure 1B, gefitinib induces
FGFR2 and FGFR3 at the protein level in cells co-expressing
EGFR and EGF ligands or gain-of-function EGFR. NSCLC cells
which do not express EGFR (Colo699, H520) or respond to
gefitinib (H226), do not undergo induction of FGFR2 or FGFR3
(Figure 1B). Consistent with a specific effect of gefitinib on the
EGFR, Erbitux, a monoclonal antibody specifically targeting the
EGFR, similarly induces FGFR2 and FGFR3 expression in the
same NSCLC cell lines that are responsive to gefitinib (Figure 1C).
Finally, partial knockdown of the EGFR with siRNA leads to
increased FGFR2 expression (Figure S1). Notably, gefitinib
treatment also induces FGFR2 protein in MCF-7 cells, a breast
cancer cell line, and 3 different head and neck cancer cell lines
(UMSCC2, UMSCC8, and HN31, Figure S1). This suggests that
the mechanism by which gefitinib induces FGFR2 and FGFR3 is
likely to be operative in diverse epithelial-derived cancer cell lines.
To further test if FGFR2 and FGFR3 are repressed downstream
EGFR signaling, H226 cells, which express high levels of FGFR2
and FGFR3, were incubated with 10 ng/mL EGF for 36 hrs. As
shown in Figure S1, EGFR activation inhibited FGFR2 and
FGFR3 protein expression but not FGFR1 expression in H226
cells. Combined, these experiments suggest that FGFR2 and
FGFR3 expression is repressed downstream of EGFR signaling
such that EGFR TKI treatment allows for FGFR2 and FGFR3
expression.
FGFR2 expression is regulated transcriptionally post
gefitinib treatment
To determine the kinetics of FGFR2 and FGFR3 induction,
quantitative RT-PCR was used to measure FGFR2 and FGFR3
mRNA expression over 4 days. In H322c cells, FGFR2 mRNA is
maximally induced within 24–48 hrs of gefitinib treatment while
FGFR3 mRNA accumulates more slowly (Figure S2). Interesting-
ly, FGFR2 and FGFR3 induction occurs quickly (1–2 days)
relative to the previously reported Met gene amplification in
response to gefitinib which required ,6 months [9]. The rapid
induction of FGFR2 and FGFR3 mRNA suggests that the fgfr2
and fgfr3 genes are not amplified but are being regulated at the
transcriptional level. To test whether mRNA levels are regulated
transcriptionally or post-transcriptionally, the 59 flanking region of
the fgfr2 gene (accession number: NT_030059) containing the
basal fgfr2 promoter [22] was cloned from genomic DNA (see
Materials and Methods) and ligated upstream of the luciferase
gene in pGL3-basic. The fgfr2-luc reporter was then transiently
transfected into H322c and H1650 cells, followed by treatment
with or without 1 mM gefitinib for 48 hrs. FGFR2 promoter
activity significantly increased after gefitinib treatment, whereas
the empty vector showed no change in activity following gefitinib
treatment (Figure 2A). Thus, increased FGFR2 mRNA is, in part,
mediated by transcriptional induction of the fgfr2 gene following
gefitinib treatment. Consistent with the failure of gefitinib to
induce FGFR2 and FGFR3 protein in NSCLC cell lines lacking
EGFR (Figure 1B), gefitinib treatment had no effect on fgfr2-luc
activity in the EGFR-null NSCLC cell line, H520 (Figure 2A).
Likewise, the monoclonal antibody, Erbitux, significantly in-
creased FGFR2 promoter activity (Figure 2B). Next, fgfr2-luc
transfected cells were treated with inhibitors of downstream
effectors of EGFR signaling, MEK (PD98059), PI3K (LY294002),
c-Src (saracatinib) and p38 MAP kinase (SB239063), for 48 hrs.
MEK inhibitor, PD98059, and c-Src inhibitor, saracatinib,
showed a similar induction of FGFR2 transcription activity as
gefitinib treatment (Figure 2C), indicating that one or both of these
signaling pathways mediate transcriptional repression of fgfr2
downstream of the EGFR. To eliminate off-target effects of
PD98059 and saracatinib, constitutively active MEK1 and c-Src
were co-transfected with the fgfr2-luc construct in H322c cells,
followed by treatment with or without gefitinib for 48 hrs.
Constitutively active MEK1 and c-Src significantly reduced fgfr2-
luc activity in response to gefitinib (Figure 2D).
FGFR induction leads to FGF stimulated signaling
through the ERK pathway
The findings in Figures 1 and 2 demonstrate transcriptional
induction of FGFR2 and FGFR3. To test whether induced FGFRs
were capable of signaling, stimulation of the ERK pathway by
exogenous FGFs was measured as a downstream target of FGFRs.
H322c and H1650 cells were cultured for 3 days in the presence or
absence of AG1478, an EGFR inhibitor, and then subsequently
incubated with FGF2 or FGF7 for 15 minutes. Cell extracts were
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of receptor activation. While untreated H322c or H1650 cells
show little or no increase in ERK activation when stimulated with
FGF2 (1.560.2, 0.960.2 fold, respectively) or FGF7 (1.260.1,
0.660.2 fold, respectively) (Figure 3A lanes 2 and 3), cells cultured
72 hrs in the presence of AG1478 to induce FGFR2 and FGFR3
have significantly lower basal ERK activity (0.460.1, 0.260.1
fold, respectively) due to blockade of the EGFR pathway,
(Figure 3A lane 7) but a marked increase in ERK phosphorylation
in response to FGF2 (5.061.2, 10.764.2 fold, respectively) and
FGF7 (6.461.0, 8.965.7 fold, respectively) (Figure 3A lanes 8 and
9). To define that ERK activation after AG1478 treatment is
FGFR mediated, cells cultured for 3 days in the presence of
AG1478 were pre-incubated with an FGFR TKI, RO4383596
[11,23], 1 hr prior to FGF2 or FGF7 stimulation. This treatment
with RO4383596 completely eliminated the FGF stimulated
phospho-ERK response following AG1478 treatment (Figure 3A
lanes 11 and 12), but has no effect on phospho-ERK when used
alone (Figure 3A lanes 4, 5, and 6). Thus, an FGFR mediated
activation of ERK is observed in both H322c and H1650 cells
following a 3-day treatment with an EGFR specific TKI. Likewise,
increased phosphorylation of FRS2 occurred in response to FGF2
stimulation after EGFR TKI treatment in H322c and H1650 cells
(Figure 3B lane 4). This response could also be blocked with the
FGFR-specific TKI (Figure S3), AZ12908010, demonstrating
direct activation of the FGFR signaling pathway (Figure 3B).
Exogenous FGF2 or FGF7 rescues growth of NSCLC cells
following treatment with an EGFR specific TKI
The previous results show that NSCLC cells cultured with
EGFR TKIs have increased FGFR2 and FGFR3 expression and
increased ERK activation in response to FGF2 or FGF7. To
directly test the role of FGFR2 and FGFR3 induction as a
mechanism of resistance to EGFR TKI treatment, anchorage-
independent growth of H322c and H1650 cells was measured.
Cells were cultured in 0.35% agar overlaid with media containing
Figure 1. Induction of FGFR2 and FGFR3 mRNA and protein in EGFR inhibitor treated NSCLC cells. A. Quantitative RT-PCR assay for
FGFR2 and FGFR3 mRNAs. Total RNA was purified from the indicated cell lines following a 3-day treatment with 1 mM gefitinib and submitted to
quantitative RT-PCR analysis of FGFR2, FGFR3 and GAPDH. (Cell lines with EGFR autocrine signaling or gain-of-function EGFR mutations: open bars;
cell lines lacking EGFR signaling: grey bars) The data are presented as fold expression over DMSO treated cells following normalization for GAPDH
mRNA. B–C. Cell lysates from the indicated NSCLC cell lines treated 3 days with or without 1 mM gefitinib or 2 mg/mL Erbitux were immunoblotted for
FGFR2, FGFR3, EGFR and the a-subunit of the NaK-ATPase as a loading control. Densitometry of FGFR2, FGFR3 and EGFR expression was normalized
relative to NaK-ATPase expression and is indicated under each immunoblot.
doi:10.1371/journal.pone.0014117.g001
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neither FGF2 nor FGF7 alone or in combination with
RO4383596 had a significant effect on colony number
(Figure 4A), FGF2 or FGF7 significantly stimulated anchorage-
independent growth of these cell lines with AG1478 treatment
(Figure 4A). As predicted, this growth response was blocked by
addition of RO4383596. In addition, HCC4006, which fails to
robustly form colonies in soft agar, showed a similar response
when stimulated with FGF2 or FGF7 in a clonogenic growth assay
(Figure 4B, see Materials and Methods). Again, the ability of
EGFR TKIs to induce FGFR2 and FGFR3 is not restricted to
NSCLC cell lines. As shown in Figure S4, FGF2 stimulated
clonogenic growth of HNSCC cell lines, UMSCC2 and HN31,
upon treatment with gefitinib. Moreover, FGF2-stimulated growth
of gefitinib treated cells was inhibited by an FGFR-specific TKI,
AZ12908010 (Figure S4).
Co-culture of H322c cells with human fibroblasts rescues
EGFR TKI induced growth inhibition in an FGFR-
dependent manner
Considering exogenous FGF2 and FGF7 can rescue anchorage
independent growth, human fibroblasts were cultured as feeder
layers with H322c cells in an anchorage-independent growth assay
to test the role of paracrine-derived FGFs in FGFR mediated
acquired resistance. As previously noted (Figure 4), H322c cells
cultured in the absence of human fibroblasts were strongly growth
inhibitedbytheEGFRTKI,gefitinib(Figure5).Bycontrast,H322c
Figure 2. Transcriptional regulation of FGFR2 following EGFR inhibitor treatment. A. H322c, H1650 or H520 cells transfected with pGL3-
basic empty control vector or FGFR2-luc reporter (see Material and Methods) and TK-renilla to estimate transfection efficiency were treated with 1 mM
gefitinib for 48 hrs. Cells were then lysed and luciferase activity measured and normalized to renilla activity. The data are the mean and SEM of 3
independent experiments. B. H322c cells transfected as above were treated with gefitinib (0.5 mM) or 2 mg/mL Erbitux for 48 hrs. The data are the
mean and SEM of 4 independent experiments. C. FGFR2-luc transfected H322c cells were treated with the indicated inhibitors (5 mM PD98059, 1 mM
saracatinib, 5 mM SB239063, or 10 mM LY294002) for 48 hrs. Luciferase expression was then measured as described above. Data are the mean and
SEM of 3 independent experiments. D. H322c cells co-transfected with FGFR2-luc and empty LXSN, constitutively active MEK1 or constitutively active
c-Src were treated for 48 hrs with 0.5 mM gefitinib. Luciferase expression was measured as described above. Data are the mean and SEM of 4
independent experiments. Statistical analysis by two-tailed t-test revealed significant increases in luciferase activity where ns indicates not significant,
* indicates p,0.05, ** indicates p,0.005 and *** indicates p,0.001.
doi:10.1371/journal.pone.0014117.g002
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inhibited by gefitinib (Figure 5). However, inclusion of the FGFR
inhibitor, AZ12908010, with gefitinib significantly blocked anchor-
age-independent growth in the presence of a fibroblast feeder layer,
although AZ12908010 has little effect on anchorage independent
growth when used alone (Figure 5). Combined, our studies indicate
that EGFR TKIs promote FGFR2 and FGFR3 as an alternate
signaling pathway capable of communicating with the surrounding
environment via secreted FGFs.
Discussion
The six hallmarks of tumorigenesis outlined by Hanahan and
Weinberg have been widely agreed upon and supported by the
Figure 3. FGF-stimulated ERK and FRS2-a activation following EGFR TKI treatment. A. NSCLC cell lines were incubated with the EGFR
inhibitor, AG1478 (0.1 mM) or DMSO, for 3 days in full media. Cells were switched to HITES for 2 hrs and subsequently incubated with the FGFR
inhibitor, RO4383596 (1 mM) or DMSO for 1 hour followed by FGF2 or FGF7 stimulation at 10 ng/mL for 15 minutes. Extracts were prepared, resolved
on SDS-PAGE and immunoblotted for phospho-ERK. The filters were subsequently stripped and reprobed for total ERK1 and ERK2 to verify equal
loading. Densitometry of phospho-ERK2 relative to total ERK2 for the designated experiment is indicated. The mean and SEM of replicate experiments
is indicated in the text of the Results section. B. NSCLC cell lines were incubated with the EGFR inhibitor, gefitinib (1 mM), gefitinib in combination
with FGFR inhibitor AZ12908010, or DMSO for 3 days in full media. Cells were then stimulated with PBS or FGF2 at 10 ng/mL for 15 minutes. Extracts
were prepared, resolved on SDS-PAGE and immunoblotted for phopho-FRS2. The filters were subsequently stripped and reprobed for NaK-ATPase a-
subunit to verify equal loading. Densitometry of phospho-FRS2 relative to NaK-ATPase is indicated under each immunoblot.
doi:10.1371/journal.pone.0014117.g003
Figure 4. FGF2 and FGF7 rescue EGFR TKI dependent growth inhibition. A. H322c and H1650 cells were analyzed for anchorage-
independent growth as described in the Materials and Methods. B. HCC4006 cells were seeded at 100 cells per 35 mm dish in full media containing
the indicated treatments and cultured for 2 weeks. Colony area was then quantified and shown as a percentage of control. The data are the mean
and SEM of 3 independent experiments. Statistical analysis by 2way ANOVA revealed significant increases in growth where * indicates p,0.05,
** indicates p,0.005 and *** indicates p,0.001.
doi:10.1371/journal.pone.0014117.g004
Acquired Resistance via FGFRs
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to the manifestation of these hallmarks have shown both successes
and failures. Even in successful cases such as imatinib targeting
Bcr-Abl, secondary mutations arise contributing to acquired
resistance in CML patients [6,7]. Therefore, as methods of
targeting oncogenic pathways in cancer cells advance, so will the
necessity for targeting mechanisms of acquired drug resistance.
Besides the accumulation of secondary mutations in targeted
proteins, a simple explanation for acquired resistance is the
selection for and emergence of alternative RTK systems. In
NSCLC cell lines and tumors, an independent phosphoproteomic
approach confirms the extensive array of RTKs that are expressed
and active [24]. Thus, there are numerous RTK candidates that
may function as alternatives to EGFR in signal transduction of
growth and transformation in NSCLC. In fact, the notion of a
receptor tyrosine kinase coactivation network has been posited as
an alternative to single RTKs working in isolation [25]. In
NSCLC, a role for c-Met and IGF-1R has been most extensively
explored [5,12,26]. In response to gefitinib treatment, amplifica-
tion of chromosomal region 7q31.1–33.3 containing the c-Met
gene has been observed, allowing c-Met activation of the PI3K/
AKT pathway in an ErbB3-dependent manner, but independent
of either EGFR or ErbB2 activation [9]. Furthermore, it was
shown that acquired resistance to gefitinib was associated with
hyperphosphorylation of the IGF-1R receptor and constitutive
association with PI3K [10]. Our data highlights the FGFR
pathway as yet another RTK system that may contribute to
acquired resistance to EGFR TKIs. Therefore, acquisition of
resistance may take months as in c-Met gene amplification [9],
weeks as in IGF-1R activation [10,27], or days as in the
transcriptional regulation of FGFR2 and FGFR3 shown in this
study. In this regard, Sharma et al. [27] have shown that cancer
cell lines undergo a rapid and reversible epigenetic response to
diverse growth inhibitors, including gefitinib, that results in drug
resistance.
The biological significance of FGFR2 and FGFR3 being
repressed in NSCLC cells in which the EGFR pathway is
activated is a question not completely addressed herein. Interest-
ingly, FGFR2 and FGFR3 mRNA expression is increased in
human bronchial epithelial cells (HBEC) grown at the air water
interface to promote differentiation into a pseudostratified
epithelium consisting of mucous secreting and ciliated cells (Figure
S5) [28]. This finding suggests that high expression of FGFR2/
FGFR3 and downstream signaling may be associated with a more
differentiated epithelial state. Preliminary data from our lab
supports an ability of EGFR TKIs to promote induction of
epithelial differentiation. Similar increases in specific measures of
epithelial differentiation in response to EGFR TKIs have also
been observed in squamous cancer cell lines [29]. In normal lung,
FGFR2 functions in epithelial cells and alveolar type II
pneumocytes to promote proliferation and differentiation, thereby
contributing to lung morphogenesis and repair [30,31]. However,
FGFR2 signaling in the tumor setting, where FGF2 and FGF7 are
likely available from the surrounding microenvironment [30,32],
may establish a paracrine pathway leading to continued cancer
cell survival, growth and maintenance of transformation in the
presence of EGFR targeted therapies.
A clear theme arising from clinical trials with single targeted
therapeutic agents is the emergence of acquired resistance
mechanisms, both delayed and rapid [26,27]. This likely reflects
a Darwinian adaptive process at the cellular level, leading to
accumulation of second-site point mutations (reviewed in [8]),
gene amplification, increased activation of distinct receptor
tyrosine kinases [9,10] or transcriptional induction of alternative
growth factor receptor pathways as detailed herein. This presents
the obvious need for strategies in which an inhibitor of the primary
molecular target and one or more inhibitors of dominant
resistance mechanisms are deployed simultaneously or consecu-
tively to enhance initial tumor cell killing or prolong an anti-tumor
response. Thus, one scenario would entail the use of an FGFR
inhibitor in combination with EGFR TKIs to prevent rapid
surmounting of growth inhibition mediated by FGFR2 and/or
FGFR3 induction. Obviously, a modern targeted therapy that
predicts the correct combination of TKIs and other inhibitors
becomes very complex. Clearly, molecular based medicine for
treatment of cancer patients must advance whereby serial
assessment of tumor markers is performed to properly choose
initial drug treatment regimens as well as second and third stage
treatments to combat evolving resistance mechanisms.
Materials and Methods
Cell Culture
All NSCLC cell lines except Colo699, H661, and H226 were
previously described by Coldren et al. [21]. The remaining lines
were obtained from the University of Colorado Cancer Center
tissue culture core. HNSCC cancer cells lines (UMSCC2,
UMSCC8, HN31) were previously described by Frederick et al.
[33]. The NSCLC and HNSCC cell lines employed in this study
were submitted to fingerprint analysis by the University of
Colorado Cancer Center to verify their authenticity. All cell lines
were routinely cultured in RPMI-1640 or DMEM (UMSCC8,
UMSCC2, HN31) growth medium supplemented with 10% fetal
bovine serum (Sigma, St. Louis, MO) at 37uC in a humidified 5%
CO2 incubator. Where indicated, the cells were switched to
HITES medium (RPMI-1640 containing 10 nM hydrocortisone,
Figure 5. Co-culture with human fibroblasts prevents EGFR TKI
dependent growth inhibition. A. H322c cells were analyzed for
anchorage-independent growth in the presence or absence of HGF-1
fibroblasts as described in the Materials and Methods. The data are the
mean and SEM of 3 independent experiments. Statistical analysis by
2way ANOVA revealed significant increases in growth where * indicates
p,0.05.
doi:10.1371/journal.pone.0014117.g005
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Na3SeO3 and 1% bovine serum albumin) to limit mitogenic inputs
from serum components. HGF-1 fibroblasts were obtained from
ATCC (Manassas, VA).
Microarray Data
Total RNA prepared from control and gefitinib-treated H322c
cells was used to probe Affymetrix U133 Plus 2.0 arrays within the
University of Colorado Cancer Center Gene Expression Core. All
data are MIAME compliant and the raw data has been deposited
in a MIAME compliant database, GEO. (Accession #: pending)
Quantitative Real-Time PCR (RT-PCR) Assay
Total RNA (5 mg) was reverse transcribed in a volume of 20 ml
using random hexamers and MMLV reverse transcriptase
(Invitrogen, Carlsbad, CA). Aliquots (5 ml) of 25-fold diluted
reverse transcription reactions were subjected to PCR in 25 ml
reactions with SYBRH green Jumpstart Taq Readymix (Sigma, St.
Louis, MO) and the primers previously described for FGFR2 [11]
or forward primer 59-CCA TCG GCA TTG ACA AGG AC-39
and reverse primer 59-GCA TCG TCT TTC AGC ATC TTC
AC-39 for FGFR3 using a My iQ real time-PCR detection system
(BioRad, Hercules, CA). GAPDH mRNA levels were measured by
quantitative RT-PCR in replicate samples as a housekeeping gene
for normalization of the different mRNA expression and the data
are presented as ‘‘Relative Expression’’.
Clonogenic and Anchorage-Independent Growth Assays
To measure the effect of EGFR TKIs on clonogenic growth,
cells were plated in 6-well plates at 100 cells/well and cultured in
full growth medium with or without 0.1 mM AG1478 (Calbiochem
San Diego, CA), 1 mM RO4383596 (Hoffmann-La Roche),
10 ng/mL FGF2 or FGF7 (PeproTech, Rocky Hill, NJ) for 2
weeks. Colonies were rinsed with PBS, stained with 200 ml of 6%
(vol/vol) glutaraldehyde, 0.5% (wt/vol) crystal violet in H2O for
30 min. at room temperature and rinsed extensively in H2O [34].
Following digital photography, the total colony area was
quantified using the MetaMorph imaging software program
(Molecular Devices, Downingtown, PA).
For measurement of anchorage-independent cell growth,
40,000 cells (H322c) or 20,000 cells (H1650) were suspended in
1.5 mL RPMI 1640 containing 10% fetal bovine serum and
0.35% DifcoTM agar noble (Becton, Dickinson and Co., Sparks,
MD) and overlaid on base layers containing 1.5 mL RPMI 1640
containing 10% fetal bovine serum and 0.5% agar noble in 6-well
plates. The wells were covered with 2 mL growth medium
containing drugs and growth factors (0.1 mMAG1478,
1 mMRO4383596, 10 ng/mL FGF2 or FGF7). This media was
replaced with fresh media containing drugs and growth factors
every 7 days. In experiments with human fibroblasts, HGF-1, co-
culture cells were plated 1 day prior to being overlaid with agar as
described above. The plates were incubated in a 37uC CO2
incubator for 21 days after which viable colonies were stained for
24 hrs with 200 mL of 1 mg/mL nitroblue tetrazolium. Following
digital photography, the colony number was quantified using the
MetaMorph imaging software program.
Immunoblot Analyses
For analysis of phospho-ERK, cells were seeded in 6-well dishes
to allow cell attachment. After 24 hrs, cells were treated with
DMSO or 0.1 mM AG1478 for 72 hrs after which media was
switched to HITES plus DMSO or AG1478 for another 2 hrs.
Subsequently, the cells were then treated with 1 mM RO4383596
or DMSO for 1 hr, after which cells were stimulated with 10 ng/
mL of FGF2, FGF7 or PBS for 15 min. For phospho-FRS2
analysis, cells were seeded in 10 cm dishes and allowed to attach.
After 24 hrs, cells were treated with DMSO, 1 mM gefitinib
(AstraZeneca, UK), or 1 mM gefitinib in combination with 0.3 mM
AZ12908010 (AstraZeneca, UK), for 72 hrs after which media
was refreshed with drugs 1 hr prior to stimulation with 10 ng/mL
FGF2 or PBS for 15 min. Growth factor and/or drug-treated
NSCLC cells were collected in 1 mL phosphate-buffered saline,
centrifuged at 1,0006g for 5 min, lysed in MAP kinase lysis buffer
(MKLB; 0.5% Triton X-100, 50 mM b-glycerophosphate
(pH 7.2), 0.1 mM Na3VO4, 2 mM MgCl2, 1 mM EGTA,
1 mM DTT, 0.3 M NaCl, 2 mg/ml leupeptin and 4 mg/ml
aprotinin) and centrifuged (5 min at 13,000 RPM). The
particulate fractions were discarded and 10 mg (phospho-ERK)
or 200 mg (phopho-FRS2) of the soluble extracts were mixed with
SDS sample buffer and submitted to SDS-PAGE. Following
electrophoretic transfer onto nitrocellulose, the filters were blocked
in 3% bovine serum albumin (Cohn Fraction V, ICN Biomedicals,
Inc., Aurora, OH) in Tris-buffered saline with 0.1% Tween 20
(TTBS) and then incubated with anti-phospho-ERK or phospho-
FRS2-a (Cell Signaling Technology, Inc, Danvers, MA, #4377
and #3864) for 16 hours at 4uC. The filters were washed
thoroughly in TTBS, then incubated with alkaline phosphatase
coupled goat anti-rabbit antibodies and developed with LumiPhos
reagent (Pierce, Rockford, IL) according to the manufacturer’s
instructions. The filters were subsequently stripped and reprobed
for total ERK1 and ERK2 or NaK-ATPase using a mixture anti-
ERK1 (sc-93) and ERK2 (sc-154) or NaK-ATPase a-subunit (sc-
21712) antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). For immunoblot analysis of FGFR1, FGFR2, FGFR3,
EGFR and the a-subunit of NaK-ATPase, NSCLC cells were
collected in phosphate-buffered saline, centrifuged (5 min, 10006
g) and suspended in MKLB after treatment with 1 mM gefitinib or
2 mg/mL Erbitux (Bristol-Myers Squibb, New York, NY). Aliquots
of the cell lysate preparations containing 75 mg of protein were
submitted to SDS-PAGE and immunoblotted for FGFR1 (sc-121),
FGFR2 (sc-122), FGFR3 (sc-13121) and NaK-ATPase a-subunit
(sc-21712) with antibodies from Santa Cruz Biotechnology (Santa
Cruz, CA). EGFR was detected with a rabbit polyclonal antibody
(#2232) from Cell Signaling Technology, Inc.
Construction of FGFR2 Promoter Luciferase Plasmid and
Luciferase Reporter Assays
Human genomic DNA (50 ng) was submitted to PCR using
Phusion polymerase, forward primer 59-GCCATTGAC-
GAAAGGGTTC-39 and reverse primer 59-TGCCTCCAC-
CAAACTTTGCTC-39 that anneal at 22165 and +267 relative
to the published transcription start site of human fgfr2 [22]. The
first 10 cycles were annealed at 67uC, 10uC above the Tm,
followed by 20 cycles with an annealing temperature at 57uC.
Purified PCR products were then cloned into pCR-Blunt using the
Zero Blunt cloning kit from Invitrogen (Carlsbad, CA) and
submitted to DNA sequencing. The FGFR2 promoter region
(22165 to +267) was shuttled into pGL3-basic (Promega,
Madison, WI) using KpnI and SmaI sites. The ligation junctions
in the FGFR2 promoter luciferase vector were verified by DNA
sequencing. Cell lines were transfected in 6-well plates with 0.5 mg
of pGL3-basic or pGL3 fgfr2 (22165 to +267) alone or in
combination with LXSN-C.A. MEK1 [35] or C.A c-Src
(Millipore, Billerica, MA) and 0.25 mg of TK-Renilla using
Effectene transfection reagent (Qiagen, Germantown, MD)
according to manufacture’s protocol. Cells were then treated with
inhibitor (1 mM gefitinib, 2 mg/mL Erbitux, 5 mM PD98059,
Acquired Resistance via FGFRs
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48 hrs at which time cells were lysed and assayed for luciferase
activity with the dual luciferase reporter assay system (Promega)
according to the manufacture’s protocol.
Supporting Information
Figure S1 FGFR2 protein is regulated downstream EGFR
signaling in cancer cell lines of epithelial origin. A. Cell lysates
from the indicated HNSCC (UMSCC2, UMSCC8, HN31) and
breast cancer (MCF-7) cell lines that had been treated with or
without 1mM gefitinib (72hrs) were immunoblotted for FGFR2
and the a-subunit of the NaK-ATPase as a loading control. B.
H322c cells transfected with 3 independent EGFR siRNA or
scramble control (Sigma, St. Louis, MO) were cultured 72 hrs and
immunoblotted for the EGFR, FGFR2 and NaK-ATPase. C.
H226 cells were cultured with PBS or EGF (10 ng/ml) for 72 hrs.
Cell lysates were immunoblotted for FGFR1, FGFR2, FGFR3,
EGFR and the a-subunit of the NaK-ATPase.
Found at: doi:10.1371/journal.pone.0014117.s001 (1.42 MB TIF)
Figure S2 Rapid induction of FGFR2 and FGFR3 mRNA.
Quantitative RT-PCR assay for FGFR2 and FGFR3 mRNAs
after treatment with 1mM gefitinib for varying amounts of time
was performed on total RNA from H322c cells and normalized for
GAPDH mRNA levels. Data are shown as fold expression over
DMSO treated cells at the indicated times. The results are a
representative of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0014117.s002 (0.18 MB TIF)
Figure S3 AZ12908010 is a specific inhibitor of FGFR
receptors. Human gingival fibroblasts (HGF-1) purchased from
ATCC were treated for 2 hrs with or without 100 nM
AZ12908010 and then for another 15 minutes with or without
FGF2 (10 ng/mL), EGF (10 ng/mL), PDGF-BB (20 ng/mL) or
IGF-1 (10 ng/mL) as indicated. Cell extracts were prepared and
submitted to SDS-PAGE and immunoblotted for phospho-ERK.
The filters were subsequently stripped and reprobed for total
ERK1 and ERK2 to verify equal loading. Only FGF2-stimulated
phospho-ERK was inhibited by AZ12908010.
Found at: doi:10.1371/journal.pone.0014117.s003 (0.56 MB TIF)
Figure S4 FGF2 rescues EGFR TKI dependent growth
inhibition in HNSCC cells. UMSCC8 and HN31 head and neck
squamous cell carcinoma lines were submitted to the clonogenic
growth assay in the presence and absence of gefitinib and/or
AZ12908010, an FGFR specific TKI (see Supplementary Figure
S3). Colonies were stained and quantified as described in Materials
and Methods.
Found at: doi:10.1371/journal.pone.0014117.s004 (1.26 MB TIF)
Figure S5 FGFR2 and FGFR3 mRNA are induced during
human bronchial epithelial cell differentiation at the air-water
interface. GEO Data Set GSE5264 containing Affymetrix Human
Genome U133 Plus 2.0 arrays of human bronchial epithelial cells
grown over a 28 day period at the air-water interface (28) were
queried for expression of EGFR, FGFR2 and FGFR3 using the
Affymetrix IDs EGFR (201983_s_at), FGFR2 (203638_s_at), and
FGFR3 (204379_s_at). Following normalization for GAPDH
expression, the data were plotted to show the relative mRNA
expression of these genes over time at the air-liquid interface. The
data points reflect the mean and SEM of the three independent
experiments performed.
Found at: doi:10.1371/journal.pone.0014117.s005 (0.42 MB TIF)
Table S1 Gene expression changes in response to gefitinib
treatment in H322c cells. Total RNA from H332c cells treated for
4 days with DMSO or 1 mM gefitinib was submitted to Affymetrix
human U133 plus 2.0 arrays. Expression levels of selected tyrosine
kinases and ligands are listed below. ("A" indicates absent and "P"
present as assessed by the Affymetrix software program).
Found at: doi:10.1371/journal.pone.0014117.s006 (0.37 MB
DOC)
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